Vericiguat
VERQUVO
What it isSoluble guanylate cyclase stimulator; heart failure with reduced ejection fraction after a worsening event.
Why this oneUnlike foundational heart-failure drugs, it is reserved for recent decompensation despite standard therapy.
What limits itHypotension and anemia limit use. Avoid other sGC stimulators; PDE5 inhibitors are not recommended. Embryo-fetal toxicity.
FDA-approved for
- chronic heart failure with reduced ejection fraction after worsening (2021)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Heart failure (reduce CV death/HF hospitalization risk) | adult | 5 mg QD (2.5 mg QD if hypotension risk) | 10 mg QD | 10 mg QD |
Titration Double dose approximately every 2 weeks to target, as tolerated
Renal Undefined
Hepatic Undefined
Instructions
- Take once daily with food
- May crush and mix with water if unable to swallow whole
Contraindications
- Concomitant use of other soluble guanylate cyclase (sGC) stimulators
- Pregnancy
Cautions
- Symptomatic hypotension
- Embryo-fetal toxicity
Adverse reactions
- Hypotension
- Anemia
Pregnancy Contraindicated; may cause fetal harm
Lactation Breastfeeding not recommended during treatment
⚠ BOXED WARNING
- Embryo-fetal toxicity
Cost, est. cash$300–$2,500/month
Generic entry2032 est.
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Vericiguat ballicule
